Mode
Text Size
Log in / Sign up
N/A N=44 Treatment

Expanded Indications in the Adult Cochlear Implant Population

Hearing Loss, Sensorineural

Enrolled (actual)
44
Serious AEs
47.7%
Results posted
Jun 2025
Primary outcome: Primary: Change in Percent Correct on Word Recognition in Quiet in Implanted Ear — 25.6 Change in percentage points

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
MED-EL SYNCHRONY/SYNCHRONY PIN Cochlear Implant System (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Med-El Corporation
Primary completion
Mar 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Percent Correct on Word Recognition in Quiet in Implanted Ear
25.6
PRIMARY
Change in Percent Correct of Words Identified for Sentences in Noise in Implanted Ear
24.1
SECONDARY
Change in Global Score on Patient-reported Outcomes in Everyday Listening Condition
-29.5
SECONDARY
Number of Participants Experiencing an Adverse Device Effect (ADE)
31
SECONDARY
Number of Participants With Residual Low-frequency Hearing
3; 24; 4; 12
SECONDARY
Change in Overall Score on Patient-reported Outcomes in Everyday Listening Condition
1.9

Summary

The purpose of this investigation is to expand FDA-approved labeling for MED-EL cochlear implants to include adults who have moderate to profound sensorineural hearing loss and obtain limited benefit from appropriately fit hearing aids.

Eligibility Criteria

Inclusion Criteria

  • Adults, 18 years of age or older at the time of implantation
  • Moderate to profound hearing loss in the low frequencies and severe to profound hearing loss in the high frequencies, bilaterally as defined by: Low-frequency PTA (250, 500, and 1000 Hz) greater than 40 dB High-frequencies not better than 65 dB (3000 Hz - 8000 Hz)
  • Sensorineural hearing loss, demonstrated by an air-bone gap of less than or equal to 10dB
  • Limited benefit from appropriately fit hearing aids, defined by CNC word score in quiet of 60% or less in the ear to be implanted and 70% or less in the non-implanted ear
  • CNC word score in quiet of greater than or equal to 10% in the ear to be implanted
  • Evidence of appropriately fit hearing aids as determined by the audiologist
  • Bilateral hearing aids should be considered standard of care, except in situations where the audiologist, physician, or potential subject determines that unilateral fit is optimal
  • Hearing aid fit should be verified through accepted measures such as functional gain or real-ear verification
  • If appropriately fit hearing aids have not been worn within the last year, a 30-day hearing aid trial must be completed prior to enrollment in the study
  • Fluent in English
  • No radiological contraindications
  • Ability to undergo general anesthesia
  • Appropriate motivation and expectation levels
  • Stated willingness to comply with all study procedures for the duration of the study

Exclusion Criteria

  • Evidence that hearing loss is retrocochlear in origin
  • Active middle ear infection
  • Skin or scalp condition precluding use of external audio processor- Suspected cognitive impairment or organic brain dysfunction
  • History of prior use of a hearing implant
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03236909). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search